Merck KGaA Collaborates with Artios Pharma for DNA Damage Cancer Therapies

 Merck KGaA Collaborates with Artios Pharma for DNA Damage Cancer Therapies

Merck KGaA Collaborates with Artios Pharma for DNA Damage Cancer Therapies

Shots:

  • Artios to receive $30M up front & near-term milestones, ~$860M/ target as option fee along with royalties on sales of each commercialized product. Additionally, Artios has opt-in rights for joint development & commercialization of the programs
  • Merck has the right to opt into exclusive development & commercialization of compounds on up to 8 targets
  • The collaboration leverages Artios’ nuclease targeting discovery platform to jointly identify multiple synthetic lethal targets for precision oncology drug candidates while Merck KGaA will utilize its expertise and resources in the field of DDR

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PSD

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post